Nangibotide for precision immunomodulation in septic shock and COVID-19

Maniraj Neupane¹, Sameer S Kadri²

Affiliations

¹ Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA; Critical Care Medicine Branch, National Heart Lung and Blood Institute, Bethesda, MD 20892, USA.
² Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA; Critical Care Medicine Branch, National Heart Lung and Blood Institute, Bethesda, MD 20892, USA. Electronic address: sameer.kadri@nih.gov.

PMID: 37269869
DOI: 10.1016/S2213-2600(23)00220-5

Comment

Nangibotide for precision immunomodulation in septic shock and COVID-19

Maniraj Neupane et al. Lancet Respir Med. 2023 Oct.

. 2023 Oct;11(10):855-857.

doi: 10.1016/S2213-2600(23)00220-5. Epub 2023 May 31.

Authors

Maniraj Neupane¹, Sameer S Kadri²

Affiliations

¹ Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA; Critical Care Medicine Branch, National Heart Lung and Blood Institute, Bethesda, MD 20892, USA.
² Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA; Critical Care Medicine Branch, National Heart Lung and Blood Institute, Bethesda, MD 20892, USA. Electronic address: sameer.kadri@nih.gov.

PMID: 37269869
DOI: 10.1016/S2213-2600(23)00220-5

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests. This work was done as part of official duties at the National Institutes of Health Clinical Center. The findings and conclusions in this Comment are those of the authors and do not necessarily represent the official position of the National Institutes of Health or the US Government.

Comment on

Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
François B, Lambden S, Fivez T, Gibot S, Derive M, Grouin JM, Salcedo-Magguilli M, Lemarié J, De Schryver N, Jalkanen V, Hicheur T, Garaud JJ, Cuvier V, Ferrer R, Bestle M, Pettilä V, Mira JP, Bouisse C, Mercier E, Vermassen J, Huberlant V, Vinatier I, Anguel N, Levy M, Laterre PF; ASTONISH investigators. François B, et al. Lancet Respir Med. 2023 Oct;11(10):894-904. doi: 10.1016/S2213-2600(23)00158-3. Epub 2023 May 31. Lancet Respir Med. 2023. PMID: 37269870 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Nangibotide for precision immunomodulation in septic shock and COVID-19

Affiliations

Nangibotide for precision immunomodulation in septic shock and COVID-19

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical